Active agents, compositions, and methods for inhibiting and reversing platelet function
AssigneeUniversity of Utah Research Foundation
InventorsDean Y, Li, Matthew Smith, Andy Weyrich
Life of this patent
Estimating the term…
Abstract
Active agents, compositions, and methods for inhibiting and reversing platelet function are provided herein. In particular embodiments, the active agents provided herein inhibit or reverse platelet function. In particular embodiments, the compositions described herein are pharmaceutical formulations. Methods of inhibiting and reversing platelet function are also provided herein. In particular embodiments, methods as described herein include administration of a Sema3E polypeptide. Further, methods of treating pathologic conditions associated with platelet function (i.e., platelet activation) and methods of screening active agent candidates are also provided.
Claims79
A composition for inhibiting platelet function, the composition comprising a Sema3E polypeptide.
A composition according to any preceding claim, wherein the Sema3E polypeptide is selected from a human Sema3E polypeptide and a mouse Sema3E polypeptide.
A composition according to any preceding claim, wherein the Sema3E polypeptide is selected from an isolated and purified, full-length, naturally occurring mammalian Sema3E polypeptide, a Sema3E polypeptide according to SEQ. ID. NO. 1, a Sema3E polypeptide according to SEQ. ID. NO. 2, a Sema3E polypeptide according to SEQ. ID. NO. 5, and a Sema3E polypeptide according to SEQ. ID. NO. 6.
A composition according to any preceding claim wherein the Sema3E polypeptide inhibits one or more of platelet spreading, adhesion, aggregation, α-granule release and clotting.
A composition according to any preceding claim, wherein the Sema3E polypeptide inhibits each of platelet spreading, adhesion, aggregation, α-granule release and clotting.
A composition according to any preceding claim, wherein the platelets are human platelets.
A composition according to any preceding claim, wherein the composition is a pharmaceutical formulation and further comprises a pharmaceutically acceptable carrier.
A composition according to any preceding claim, wherein the Sema3E polypeptide inhibits activation of Rap1b.
A composition according to any preceding claim, wherein the Sema3E polypeptide binds to and is biologically active at a plexin receptor.
A method for inhibiting the function of platelet cells, the method comprising providing a Sema3E polypeptide and exposing said platelet cells to said Sema3E polypeptide.
A method for reversing the function of platelet cells, the method comprising providing a Sema3E polypeptide and exposing said platelet cells to said Sema3E polypeptide.
A method for treating a patient at risk for a pathologic condition associated with one or more platelet function, the method comprising identifying a patient at risk for a pathologic condition associated with one or more of platelet spreading, adhesion, aggregation, α-granule release and clotting and administering a therapeutically effective amount of a Sema3E polypeptide to said patient.
A method for treating a patient suffering from a pathologic condition associated with one or more platelet function, the method comprising identifying a patient suffering from a pathologic condition associated with one or more of platelet spreading, adhesion, aggregation, α-granule release and clotting and administering a therapeutically effective amount of a Sema3E polypeptide to said patient.
Dependencies are inferred from the claim text.